Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides

C Tintori, G Iovenitti, ER Ceresola, R Ferrarese, C Zamperini, A Brai, G Poli, E Dreassi, V Cagno, D Lembo, F Canducci, Maurizio Botta

Research output: Contribution to journalArticle

Abstract

Although highly active antiretroviral therapies (HAART) remarkably increased life expectancy of HIV positive people, the rate of novel HIV-1 infections worldwide still represent a major concern. In this context, pre-exposure prophylaxis (PrEP) approaches such as vaginal microbicide gels topically releasing antiretroviral drugs, showed to have a striking impact in limiting HIV-1 spread. Nevertheless, the co-presence of other genital infections, particularly those due to HSV-1 or 2, constitute a serious drawback that strongly limits the efficacy of PrEP approaches. For this reason, combinations of different compounds with mixed antiviral and antiretroviral activity are thoroughly investigated Here we report the synthesis and the biological evaluation of a novel series of rhodanine derivatives, which showed to inhibit both HIV-1 and HSV-1/2 replication at nanomolar concentration, and were found to be active also on acyclovir resistant HSV-2 strains. The compounds showed a considerable reduction of activity in presence of serum due to a high binding to serum albumin, as determined through in vitro ADME evaluations. However, the most promising compound of the series maintained a considerable activity in gel formulation, with an EC50comparable to that obtained for the reference drug tenofovir. Moreover, the series of compounds showed pharmacokinetic properties suitable for topical formulation, thus suggesting that the novel rhodanine derivatives could represent effective agents to be used as dual anti HIV/HSV microbicides in PrEP approaches. © 2018 Tintori et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Original languageEnglish
Article numbere0198478
JournalPLoS One
Volume13
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Rhodanine
Human Herpesvirus 2
Tenofovir
Anti-Infective Agents
Human immunodeficiency virus 1
HIV-1
disease control
anti-infective agents
chemical derivatives
Gels
Human Herpesvirus 1
HIV
Derivatives
Pharmacokinetics
Acyclovir
gels
Serum Albumin
Foams and Jellies Vaginal Creams
Pharmaceutical Preparations
Antiviral Agents

Cite this

Tintori, C., Iovenitti, G., Ceresola, ER., Ferrarese, R., Zamperini, C., Brai, A., ... Botta, M. (2018). Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PLoS One, 13(6), [e0198478]. https://doi.org/10.1371/journal.pone.0198478

Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. / Tintori, C; Iovenitti, G; Ceresola, ER; Ferrarese, R; Zamperini, C; Brai, A; Poli, G; Dreassi, E; Cagno, V; Lembo, D; Canducci, F; Botta, Maurizio.

In: PLoS One, Vol. 13, No. 6, e0198478, 2018.

Research output: Contribution to journalArticle

Tintori, C, Iovenitti, G, Ceresola, ER, Ferrarese, R, Zamperini, C, Brai, A, Poli, G, Dreassi, E, Cagno, V, Lembo, D, Canducci, F & Botta, M 2018, 'Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides', PLoS One, vol. 13, no. 6, e0198478. https://doi.org/10.1371/journal.pone.0198478
Tintori C, Iovenitti G, Ceresola ER, Ferrarese R, Zamperini C, Brai A et al. Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PLoS One. 2018;13(6). e0198478. https://doi.org/10.1371/journal.pone.0198478
Tintori, C ; Iovenitti, G ; Ceresola, ER ; Ferrarese, R ; Zamperini, C ; Brai, A ; Poli, G ; Dreassi, E ; Cagno, V ; Lembo, D ; Canducci, F ; Botta, Maurizio. / Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. In: PLoS One. 2018 ; Vol. 13, No. 6.
@article{b87cf9a3ba9041e0be5da131f4177790,
title = "Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides",
abstract = "Although highly active antiretroviral therapies (HAART) remarkably increased life expectancy of HIV positive people, the rate of novel HIV-1 infections worldwide still represent a major concern. In this context, pre-exposure prophylaxis (PrEP) approaches such as vaginal microbicide gels topically releasing antiretroviral drugs, showed to have a striking impact in limiting HIV-1 spread. Nevertheless, the co-presence of other genital infections, particularly those due to HSV-1 or 2, constitute a serious drawback that strongly limits the efficacy of PrEP approaches. For this reason, combinations of different compounds with mixed antiviral and antiretroviral activity are thoroughly investigated Here we report the synthesis and the biological evaluation of a novel series of rhodanine derivatives, which showed to inhibit both HIV-1 and HSV-1/2 replication at nanomolar concentration, and were found to be active also on acyclovir resistant HSV-2 strains. The compounds showed a considerable reduction of activity in presence of serum due to a high binding to serum albumin, as determined through in vitro ADME evaluations. However, the most promising compound of the series maintained a considerable activity in gel formulation, with an EC50comparable to that obtained for the reference drug tenofovir. Moreover, the series of compounds showed pharmacokinetic properties suitable for topical formulation, thus suggesting that the novel rhodanine derivatives could represent effective agents to be used as dual anti HIV/HSV microbicides in PrEP approaches. {\circledC} 2018 Tintori et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
author = "C Tintori and G Iovenitti and ER Ceresola and R Ferrarese and C Zamperini and A Brai and G Poli and E Dreassi and V Cagno and D Lembo and F Canducci and Maurizio Botta",
year = "2018",
doi = "10.1371/journal.pone.0198478",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides

AU - Tintori, C

AU - Iovenitti, G

AU - Ceresola, ER

AU - Ferrarese, R

AU - Zamperini, C

AU - Brai, A

AU - Poli, G

AU - Dreassi, E

AU - Cagno, V

AU - Lembo, D

AU - Canducci, F

AU - Botta, Maurizio

PY - 2018

Y1 - 2018

N2 - Although highly active antiretroviral therapies (HAART) remarkably increased life expectancy of HIV positive people, the rate of novel HIV-1 infections worldwide still represent a major concern. In this context, pre-exposure prophylaxis (PrEP) approaches such as vaginal microbicide gels topically releasing antiretroviral drugs, showed to have a striking impact in limiting HIV-1 spread. Nevertheless, the co-presence of other genital infections, particularly those due to HSV-1 or 2, constitute a serious drawback that strongly limits the efficacy of PrEP approaches. For this reason, combinations of different compounds with mixed antiviral and antiretroviral activity are thoroughly investigated Here we report the synthesis and the biological evaluation of a novel series of rhodanine derivatives, which showed to inhibit both HIV-1 and HSV-1/2 replication at nanomolar concentration, and were found to be active also on acyclovir resistant HSV-2 strains. The compounds showed a considerable reduction of activity in presence of serum due to a high binding to serum albumin, as determined through in vitro ADME evaluations. However, the most promising compound of the series maintained a considerable activity in gel formulation, with an EC50comparable to that obtained for the reference drug tenofovir. Moreover, the series of compounds showed pharmacokinetic properties suitable for topical formulation, thus suggesting that the novel rhodanine derivatives could represent effective agents to be used as dual anti HIV/HSV microbicides in PrEP approaches. © 2018 Tintori et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

AB - Although highly active antiretroviral therapies (HAART) remarkably increased life expectancy of HIV positive people, the rate of novel HIV-1 infections worldwide still represent a major concern. In this context, pre-exposure prophylaxis (PrEP) approaches such as vaginal microbicide gels topically releasing antiretroviral drugs, showed to have a striking impact in limiting HIV-1 spread. Nevertheless, the co-presence of other genital infections, particularly those due to HSV-1 or 2, constitute a serious drawback that strongly limits the efficacy of PrEP approaches. For this reason, combinations of different compounds with mixed antiviral and antiretroviral activity are thoroughly investigated Here we report the synthesis and the biological evaluation of a novel series of rhodanine derivatives, which showed to inhibit both HIV-1 and HSV-1/2 replication at nanomolar concentration, and were found to be active also on acyclovir resistant HSV-2 strains. The compounds showed a considerable reduction of activity in presence of serum due to a high binding to serum albumin, as determined through in vitro ADME evaluations. However, the most promising compound of the series maintained a considerable activity in gel formulation, with an EC50comparable to that obtained for the reference drug tenofovir. Moreover, the series of compounds showed pharmacokinetic properties suitable for topical formulation, thus suggesting that the novel rhodanine derivatives could represent effective agents to be used as dual anti HIV/HSV microbicides in PrEP approaches. © 2018 Tintori et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

U2 - 10.1371/journal.pone.0198478

DO - 10.1371/journal.pone.0198478

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0198478

ER -